ARVN Q2 2024 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$77M+40.4% YoY

Gross Profit

$75M97.8% margin

Operating Income

-$49M-63.4% margin

Net Income

-$35M-46.0% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

+202.4%

Cash Flow

Operating Cash Flow

$50M

Free Cash Flow

$50M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$680M

Stockholders' Equity

$600M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$77M	$55M	+40.4%
Gross Profit	$75M	$53M	+41.4%
Operating Income	-$49M	-$75M	+35.0%
Net Income	-$35M	-$67M	+47.1%

Revenue Segments

License

$130M100%